• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Vaxess raises $9M to support shelf-stable vaccine patch

September 13, 2023 By Sean Whooley

Vaxess Technologies MIMIX vaccine patch
[Image from the Vaxess website]
Vaxess Technologies announced today that it raised an additional $9 million in venture capital funding to support its vaccine delivery technology.

Cambridge, Massachusetts-based Vaxess develops a shelf-stable vaccine patch with the potential for self-application.

The company’s MiMix system features sustained-release technology for administering vaccines and therapeutics. For vaccines, its controlled release simulates the pace of a natural infection. The company said this helps the body produce a slow, strong and enduring immune response ramp. Because it doesn’t require refrigeration, it can be shipped to and applied in low-resource settings, too.

The latest round of funding brings the company’s total equity and non-dilutive funds raised to more than $80 million. RA Capital, The Engine, GHIC and Ulu Ventures all contributed to this round.

“As we head into the fall and winter months, we’ll be reminded that there’s still much work to be done around increasing vaccination rates and improving vaccine efficacy for a range of diseases, from flu to COVID,” said Michael Schrader, co-founder and CEO of Vaxess. “This new funding — which comes from an extraordinary group of VCs focused on technology, biopharma, and broader societal impact — will enable Vaxess to accelerate mRNA vaccine patch development efforts, and work towards fundamentally changing how mRNA vaccines are distributed and administered.”

More about Vaxess and its vaccine delivery system

The MiMix patch features a soluble microarray with tips that gradually dissolve into the body after removing the patch. These tips release their payload of vaccines over time, mimicking how natural infections interact with the body.

By allowing the immune system to mount a stronger, more durable response, they could provide more protection against disease, Vaxess says. The dissolving needles also eliminate any sharps hazard for simple patch disposal post-administration.

In December 2022, the company reported positive interim results from a first-in-human trial of its influenza vaccine patch. Vaxess raised $37 million in a Series B round within the last year, also growing its team by more than 30%. The team operates at its corporate headquarters in Cambridge and its GMP manufacturing facility in Woburn, Massachusetts.

Last month, Vaxess announced a collaboration with AstraZeneca. The companies aim to evaluate an RNA-based pandemic influenza prototype vaccine in patch format. In April, Vaxess announced mRNA stability results from tests assessing the potential for room-temperature storage.

The company’s focus now centers around translating the mRNA LNPs stored in silk fibroin matrices into a MiMix sustained-release patch.

“Imagine a world where vaccines don’t require trips to the clinic, cold chain transport, or needle and syringe injection — this would meaningfully expand access to preventative care,” said Kathy Chen, partner at Ulu Ventures. “With proven distribution advantages and enhanced efficacy of protection, Vaxess’s unique approach could play a pivotal role in improving public health globally. We’re excited to work with the company as it commercializes its first patches.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Technology Tagged With: Vaxess Technologies

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS